Biomerica Gains MHRA Nod for H. pylori Test, Eyes UK Market Expansion
Event summary
- Biomerica received MHRA registration for its hp+detect™ H. pylori diagnostic test on March 5, 2026.
- The test is now authorized for commercial sale in Great Britain.
- Biomerica is in active discussions with UK partners to enter the diagnostic laboratory market.
- H. pylori infects 45% of Europe’s five largest countries and is a Class 1 carcinogen per WHO.
The big picture
Biomerica’s MHRA approval positions it to address a significant unmet need in the UK, where H. pylori remains a major public health challenge. The move aligns with global trends toward non-invasive diagnostics amid rising antimicrobial resistance. Success here could serve as a blueprint for expansion into other European markets.
What we're watching
- Market Penetration
- How quickly Biomerica can secure partnerships and scale commercialization in the UK.
- Regulatory Momentum
- Whether this approval accelerates MHRA or other international registrations.
- Competitive Dynamics
- The pace at which competitors respond with similar diagnostic solutions.
Related topics